iiinova — where your digital self keeps evolving

Reposted by Allison Betof Warner, MD, PhD

American Society of Clinical Oncology @ascocancer.bsky.social · 17/04/2026

Following FDA approval of lifileucel for advanced melanoma in early 2024, U.S. centers have been learning how to best deliver this novel “living” drug. For #ASCODailyNews, @maxjulve.bsky.social & @drbetofmdphd.bsky.social discuss the real-world challenges facing clinicians: bit.ly/48nBPor

101

Reposted by Allison Betof Warner, MD, PhD

Pauline Funchain @funchainmd.bsky.social · 28/02/2026

Good afternoon Vancouver 🌞🏔️ It’s 2026 and melanoma data continue to move in TIL 🏋️‍♀️ @drbetofmdphd.bsky.social discusses 10 year melanoma survival data for patients who have experienced complete response with earlier versions of TIL #MovingTheGoalPosts #CMC26 @stanford-cancer.bsky.social

031

Allison Betof Warner, MD, PhD @drbetofmdphd.bsky.social · 27/02/2026

Stanford #Melanoma’s @funchainmd.bsky.social leading us through a fantastic discussion of immune checkpoint toxicity #irAE in patients with pre-existing autoimmune disease. #CMC26 @stanforduniversity.bsky.social

161

Reposted by Allison Betof Warner, MD, PhD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 06/02/2026

The #OncoAlertColloquium 2026 Thoracic Malignancies🚨 DAY FIVE Presentation by Dr. Gilberto Lopes🇺🇸 : Year in Review Early #NSCLC REGISTER HERE TO WATCH: buff.ly/xwD5G2D Practice-changing research in 2025 in early NSCLC 🚀

001

Reposted by Allison Betof Warner, MD, PhD

Society for Immunotherapy of Cancer @sitcancer.bsky.social · 06/06/2025

New Journal for ImmunoTherapy of Cancer (JITC) commentary: Role of high-dose interleukin-2 for melanoma in the age of cellular therapy bit.ly/4jwhLmm @drbetofmdphd.bsky.social #JITC #research #cancer 🧪

New Journal for ImmunoTherapy of Cancer (JITC) commentary: Role of high-dose interleukin-2 for melanoma in the age of cellular therapy https://bit.ly/4jwhLmm
@drbetofmdphd.bsky.social #JITC #research #cancer

011

Reposted by Allison Betof Warner, MD, PhD

Pauline Funchain @funchainmd.bsky.social · 02/06/2025

Melanoma rapid oral #9 ➡️ OBX-115, engineered TIL with membrane bound IL15 regulated with acetazolamide -for 6pt receiving RP2D, 67% ORR, 1 CR, 100% DCR -mDOR not reached Jason Chesney U Louisville and @drbetofmdphd.bsky.social @stanford-cancer.bsky.social #ASCO25 @ascocancer.bsky.social

073

Allison Betof Warner, MD, PhD @drbetofmdphd.bsky.social · 11/04/2025

An entire day for solid tumor at #iwCART25! How far we’ve come in solid tumor cell therapy- 2 approvals since I was at this meeting last year! Looking forward to a great meeting.

000

Reposted by Allison Betof Warner, MD, PhD

Pauline Funchain @funchainmd.bsky.social · 25/03/2025

Pushing through boundaries in solid tumor cell therapy @stanford-cancer.bsky.social 📈 ➡️ only 1 of 10 centers that offers sarcoma TCR-T ➡️ 50% DCR with TIL in melanoma brain mets and promising safety signal, no seizures or hemorrhages 🤞🙏 @drbetofmdphd.bsky.social @stevenartandi.bsky.social

0142

Reposted by Allison Betof Warner, MD, PhD

Jason Luke, MD, FACP, FASCO @jasonlukemd.bsky.social · 14/02/2025

Enjoyed discussing LAG3 targeting #melanoma w @drbetofmdphd.bsky.social Major role for relatlimab while fianlimab data look as good/better so far! Field has been waiting long time for RELA-098 but Ph3 studies abound for cemi-fian metastatic, adjuvant and peri-op! www.medscape.org/viewarticle/...

031

Reposted by Allison Betof Warner, MD, PhD

Pauline Funchain @funchainmd.bsky.social · 03/02/2025

Fantastic panel moderated by @drbetofmdphd.bsky.social - so many melanoma trials open/opening in the Bay Area. Great company, great colleagues, and great movement to make melanoma outcomes better here in the Bay Area, and everywhere 🖤 Thanks to ANCO for continuing to elevate oncology in NoCal ⛰️

011

Allison Betof Warner, MD, PhD @drbetofmdphd.bsky.social · 01/02/2025

What a great Melanoma & Developmental Therapeutics Session at the @ANCO_News conference! We discussed breakthroughs from 2024 and covered exciting new trial opportunities available in the Bay Area. What a team! 🤩 @funchainmd.bsky.social

040

Allison Betof Warner, MD, PhD @drbetofmdphd.bsky.social · 13/01/2025

Another landmark day for solid tumor cell therapy at @stanforduniversity.bsky.social Cancer Institute with our first infusion of FDA approved afami-cel (Tecelra), an engineered TCR T cell for synovial #sarcoma. We are thrilled to make this available to our patients!! #medsky #oncsky

171

Reposted by Allison Betof Warner, MD, PhD

Pauline Funchain @funchainmd.bsky.social · 13/01/2025

New year, new adventures at #MedSky - oncology faculty opening for solid tumor cell therapy position 🧫@stanforduniversity.bsky.social, with preference for TIL/melanoma experience. Please contact me or @drbetofmdphd.bsky.social for more details!

043

Reposted by Allison Betof Warner, MD, PhD

Miguel Perales MD @drmiguelperales.bsky.social · 08/01/2025

At the White House Cell and Gene Therapy Forum with my former @mskcancercenter.bsky.social colleague Kamal Menghrajani #cancermoonshot #whitehousecgt #genetherapy #CARTcells

0182

Reposted by Allison Betof Warner, MD, PhD

Miguel Perales MD @drmiguelperales.bsky.social · 24/12/2024

Merry Christmas from @mskcancercenter.bsky.social 🎅🎄

081

Allison Betof Warner, MD, PhD @drbetofmdphd.bsky.social · 19/12/2024

SOLID TUMOR CELL THERAPY position at Stanford. We are searching for a clinical investigator (MD, MD/PhD, or equiv) with expertise in solid tumor cell therapy, preference for experience with melanoma/TILs to join our growing team! facultypositions.stanford.edu/en-us/job/49...

facultypositions.stanford.edu

Stanford | Faculty Positions: Details - Assistant or Associate Professor, Solid Tumor Cell Therapy

083

Allison Betof Warner, MD, PhD @drbetofmdphd.bsky.social · 17/12/2024

As an alum of @mskcancercenter.bsky.social, this brings back some really warm memories. The holiday hallway is such a labor of love which is emblematic of the best of MSK! www.instagram.com/reel/DDrsAab...

instagram.com

Welcome back to Instagram. Sign in to check out what your friends, family & interests have been capturing & sharing around the world.

000

Reposted by Allison Betof Warner, MD, PhD

Stephen Liu @stephenvliu.bsky.social · 16/12/2024

Development of two next gen IO molecules has been discontinued. Vibostolimab (anti #TIGIT) and favezelimab (anti LAG3) programs both being shuttered. Development in this space has been significantly hampered by the lack of predictive biomarkers. www.merck.com/news/merck-p...

merck.com

Merck Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab - Merck.com

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the discontinuation of the clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezeli...

0122

Allison Betof Warner, MD, PhD @drbetofmdphd.bsky.social · 13/12/2024

Wishing you happy and HEALTHY holidays from our @stanforduniversity.bsky.social Melanoma Oncology clinical and research team. We had a very festive celebration (including a grinch sighting!). We’ve grown tremendously over the last year- can’t wait for what’s in store for 2025!

061

Reposted by Allison Betof Warner, MD, PhD

Jon Lim, FRCP PhD @drjonlim.bsky.social · 12/12/2024

📚 In conjunction with #ESMOImmuno24, we had our annual #ESMO #IOTECH Editorial Board meeting today - delighted to see many more academics now here 🦋. 🎯 EiC: @haanenjohn.bsky.social Section Editors: @michalbassani.bsky.social (NeoAg/TILs) @danielathommen.bsky.social (Biomarkers/novel IO targets)...

153

Reposted by Allison Betof Warner, MD, PhD

Melanoma Research Alliance @melanomaresearch.bsky.social · 11/12/2024

From our recent webinar, Dr. Evan Lipson shares essential questions every melanoma patient should ask after their diagnosis about testing and treatment options. Empower yourself with knowledge and follow MRA to stay informed! #MelanomaAwareness

001

Reposted by Allison Betof Warner, MD, PhD

Science News @scinews.bsky.social · 09/12/2024

Mannose metabolism reshapes T cell differentiation to enhance anti-tumor immunity #CancerCell "Cell-intrinsic mannose metabolism is a physiological regulator of CD8+ T cell fate, decoupling proliferation/expansion from differentiation" www.cell.com/cancer-cell/...

0333

Reposted by Allison Betof Warner, MD, PhD

Dr. Patrick Hwu @patrickhwumd.bsky.social · 07/12/2024

#ScienceSaturday ➡️ Did you know that some chemotherapies can enhance the immune response against #cancer? ❓ How might we potentiate this?

1163

Reposted by Allison Betof Warner, MD, PhD

Science News @scinews.bsky.social · 07/12/2024

Ageing of stem cells reduces their capacity to form tumours #Nature @natureportfolio.bsky.social "Most human cancers initiate at a young age, highlighting the importance of directing cancer prevention efforts towards young individuals." www.nature.com/articles/s41...

nature.com

Ageing limits stemness and tumorigenesis by reprogramming iron homeostasis - Nature

Studies using mouse models of lung adenocarcinoma identify an association between age, iron homeostasis and tumour initiation potential that involves NUPR1 and lipocalin-2.

04612

Allison Betof Warner, MD, PhD @drbetofmdphd.bsky.social · 08/12/2024

Traveling home from the 2024 #ImmunotherapyBridge and #MelanomaBridge meetings in Napoli. We ate/drank ALL the food/wine, we debated, we collaborated, and we strengthened our community. I even got to debate one of my #she-roes @chrystalpaulos.bsky.social. Every year this meeting gets better!